Compare FULT & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULT | CRNX |
|---|---|---|
| Founded | 1882 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | 1995 | 2018 |
| Metric | FULT | CRNX |
|---|---|---|
| Price | $24.16 | $84.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $21.75 | ★ $76.75 |
| AVG Volume (30 Days) | 1.8M | ★ 3.2M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.55% | N/A |
| EPS Growth | ★ 32.48 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $276,768,000.00 | $1,039,000.00 |
| Revenue This Year | $6.39 | $720.10 |
| Revenue Next Year | $5.52 | $184.67 |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.60 | $28.62 |
| 52 Week High | $25.23 | $84.35 |
| Indicator | FULT | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 90.25 |
| Support Level | $24.14 | $83.47 |
| Resistance Level | $24.98 | N/A |
| Average True Range (ATR) | 0.46 | 0.24 |
| MACD | -0.12 | -1.64 |
| Stochastic Oscillator | 32.11 | 96.57 |
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.